BioNTech inks CAR-T partnership with Autolus

08 Feb 2024
www.pharmamanufacturing.com
License out/inCell TherapyImmunotherapyADC
BioNTech and UK-based biotech Autolus Therapeutics have announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization.
In connection with the alliance, the companies entered into a license and option agreement and a securities purchase agreement.
Per the license and option agreement, BioNTech will make a cash payment of $50 million. In exchange, BioNTech will get access to Autolus’ commercial and clinical site network and manufacturing capacities in the UK and commercial supply infrastructure in order to accelerate the development of its experimental CAR-T thereapy, BNT211, in additional CLDN6+ tumorCLDN6+ tumor types.
BioNTech will support launch and expanded development of Autolus’ lead cell therapy candidate, obe-cel, and will receive a royalty on net sales. The CD19 CAR-T therapy is currently in the hands of regulators for approval in relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Additionally, BioNTech will get co-commercialization options for Autolus’ AUTO1/22 and AUTO6NG programs and the option to access a suite of Autolus target binders and cell programming technologies to support BioNTech’s development of in vivo cell therapy and ADC candidates.
In terms of the securities purchase portion of the deal, BioNTech has agreed to buy $200 million of Autolus’ American depositary shares in a private placement. BioNTech will have the right to appoint a director to the Board of Autolus.
The collaboration is the latest in a spree of deal-making for BioNTech. Last month, the German biotech agreed to pay WuXi $20 million upfront for exclusive rights to two investigational monoclonal antibodies. In November, BioNTech signed a potential $1 billion deal with Zhuhai-based Biotheus to develop a bispecific antibody candidate against solid tumors. In October, BioNTech announced a potential $1 billion collaboration with China-based MediLink Therapeutics that centered on the development of an ADC targeting HER3.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.